Taxane-based chemotherapy in senior adults with metastatic castration-resistant prostate cancer (mCRPC): A prospective international registry.

e15122 Background: Docetaxel every 3 weeks is the standard of care in mCRPC. Efficacy and toxicity of taxanes in older men (70+) is poorly documented. Their enrolment in randomized trials is limited by exclusion criteria. This prospective international registry evaluates taxane toxicity and efficacy in such men in real life. Methods: 333 men with mCRPC (median age 76) were evaluated. PS, grade 3-4 comorbidities (Cumulative Illness Scoring Rate-Geriatrics [CISR-G]), dependence (Activity Daily Living [ADL], Instrumental ADL [IADL]), nutritional status, primary therapy received and outcomes (overall survival (OS), progression-free survival (PFS), best clinical benefit [based on pain, analgesic consumption, PS], PSA response, toxicity) were collected. Follow-up under therapy was 6 months. Results: In all, 24.0% had PS ≥2, 13.5% grade 3-4 comorbidities, 21% were dependent in ≥1 IADL, 15.6% in ≥1 ADL and 12.8% had a weight loss ≥5% within the past 3 months. According to SIOG (International Society of Geriatric ...